264 related articles for article (PubMed ID: 31915427)
1. Neurochemical and Behavioral Profiling in Male and Female Rats of the Psychedelic Agent 25I-NBOMe.
Miliano C; Marti M; Pintori N; Castelli MP; Tirri M; Arfè R; De Luca MA
Front Pharmacol; 2019; 10():1406. PubMed ID: 31915427
[TBL] [Abstract][Full Text] [Related]
2. 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOME): A Harmful Hallucinogen Review.
Kamińska K; Świt P; Malek K
J Anal Toxicol; 2021 Jan; 44(9):947-956. PubMed ID: 32128596
[TBL] [Abstract][Full Text] [Related]
3. Contribution of serotonin receptor subtypes to hallucinogenic activity of 25I-NBOMe and to its effect on neurotransmission.
Herian M; Wojtas A; Sobocińska MK; Skawski M; González-Marín A; Gołembiowska K
Pharmacol Rep; 2020 Dec; 72(6):1593-1603. PubMed ID: 33174181
[TBL] [Abstract][Full Text] [Related]
4. Hallucinogen-Like Action of the Novel Designer Drug 25I-NBOMe and Its Effect on Cortical Neurotransmitters in Rats.
Herian M; Wojtas A; Kamińska K; Świt P; Wach A; Gołembiowska K
Neurotox Res; 2019 Jul; 36(1):91-100. PubMed ID: 30989482
[TBL] [Abstract][Full Text] [Related]
5. Tolerance to neurochemical and behavioral effects of the hallucinogen 25I-NBOMe.
Herian M; Skawski M; Wojtas A; Sobocińska MK; Noworyta K; Gołembiowska K
Psychopharmacology (Berl); 2021 Aug; 238(8):2349-2364. PubMed ID: 34032876
[TBL] [Abstract][Full Text] [Related]
6. Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT
Eshleman AJ; Wolfrum KM; Reed JF; Kim SO; Johnson RA; Janowsky A
Biochem Pharmacol; 2018 Dec; 158():27-34. PubMed ID: 30261175
[TBL] [Abstract][Full Text] [Related]
7. Effect of
Tirri M; Bilel S; Arfè R; Corli G; Marchetti B; Bernardi T; Boccuto F; Serpelloni G; Botrè F; De-Giorgio F; Golembiowska K; Marti M
Front Psychiatry; 2022; 13():875722. PubMed ID: 35530025
[TBL] [Abstract][Full Text] [Related]
8. Neurotoxicological profile of the hallucinogenic compound 25I-NBOMe.
Herian M; Wojtas A; Maćkowiak M; Wawrzczak-Bargiela A; Solarz A; Bysiek A; Madej K; Gołembiowska K
Sci Rep; 2022 Feb; 12(1):2939. PubMed ID: 35190675
[TBL] [Abstract][Full Text] [Related]
9. Nanosensor for Sensitive Detection of the New Psychedelic Drug 25I-NBOMe.
Garrido E; Alfonso M; Díaz de Greñu B; Lozano-Torres B; Parra M; Gaviña P; Marcos MD; Martínez-Máñez R; Sancenón F
Chemistry; 2020 Mar; 26(13):2813-2816. PubMed ID: 31943443
[TBL] [Abstract][Full Text] [Related]
10. Retrospective Demonstration of 25I-NBOMe Acute Poisoning Using Hair Analysis.
Ameline A; Farrugia A; Raul JS; Kintz P
Curr Pharm Biotechnol; 2017; 18(10):786-790. PubMed ID: 29189143
[TBL] [Abstract][Full Text] [Related]
11. Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response.
Halberstadt AL; Geyer MA
Neuropharmacology; 2014 Feb; 77():200-7. PubMed ID: 24012658
[TBL] [Abstract][Full Text] [Related]
12. 25I-NBOMe, a phenethylamine derivative, induces adverse cardiovascular effects in rodents: possible involvement of p21 (CDC42/RAC)-activated kinase 1.
Yoon KS; Gu SM; Cha HJ; Kim YH; Yun J; Lee JM
Drug Chem Toxicol; 2022 Mar; 45(2):898-906. PubMed ID: 32597268
[TBL] [Abstract][Full Text] [Related]
13. Locomotor and discriminative stimulus effects of four novel hallucinogens in rodents.
Gatch MB; Dolan SB; Forster MJ
Behav Pharmacol; 2017 Aug; 28(5):375-385. PubMed ID: 28537942
[TBL] [Abstract][Full Text] [Related]
14. A retrospective analysis of the "Neverending Trip" after administration of a potent full agonist of 5-HT2A receptor - 25I-NBOMe.
Schetz D; Schetz A; Kocić I
Biomed Pharmacother; 2022 Feb; 146():112295. PubMed ID: 34980551
[TBL] [Abstract][Full Text] [Related]
15. 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): clinical case with unique confirmatory testing.
Stellpflug SJ; Kealey SE; Hegarty CB; Janis GC
J Med Toxicol; 2014 Mar; 10(1):45-50. PubMed ID: 23872917
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of use and acute toxicity associated with the use of NBOMe drugs.
Wood DM; Sedefov R; Cunningham A; Dargan PI
Clin Toxicol (Phila); 2015 Feb; 53(2):85-92. PubMed ID: 25658166
[TBL] [Abstract][Full Text] [Related]
17. NBOMes-Highly Potent and Toxic Alternatives of LSD.
Zawilska JB; Kacela M; Adamowicz P
Front Neurosci; 2020; 14():78. PubMed ID: 32174803
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the hepatic cytochrome P450 enzymes involved in the metabolism of 25I-NBOMe and 25I-NBOH.
Nielsen LM; Holm NB; Leth-Petersen S; Kristensen JL; Olsen L; Linnet K
Drug Test Anal; 2017 May; 9(5):671-679. PubMed ID: 27400739
[TBL] [Abstract][Full Text] [Related]
19. Designer Drug, 25D-NBOMe, Has Reinforcing and Rewarding Effects through Change of a Dopaminergic Neurochemical System.
Lee JG; Hur KH; Hwang SB; Lee S; Lee SY; Jang CG
ACS Chem Neurosci; 2023 Aug; 14(15):2658-2666. PubMed ID: 37463338
[TBL] [Abstract][Full Text] [Related]
20. Case series: toxicity from 25B-NBOMe--a cluster of N-bomb cases.
Gee P; Schep LJ; Jensen BP; Moore G; Barrington S
Clin Toxicol (Phila); 2016; 54(2):141-6. PubMed ID: 26621342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
